Real-time Estimate
Cboe BZX
11:14:45 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
14.4
USD
|
+5.22%
|
|
+10.43%
|
-34.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,741
|
4,502
|
2,506
|
2,269
|
1,301
|
823.9
|
-
|
-
|
Enterprise Value (EV)
1 |
2,732
|
2,841
|
763.7
|
996.6
|
547.7
|
327.6
|
493.7
|
350.6
|
P/E ratio
|
-5.4
x
|
7.57
x
|
-5.45
x
|
-4.25
x
|
-2.39
x
|
-2.08
x
|
-2.63
x
|
-4.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
545
x
|
4.04
x
|
397
x
|
295
x
|
15
x
|
19.3
x
|
6.21
x
|
2.72
x
|
EV / Revenue
|
398
x
|
2.55
x
|
121
x
|
130
x
|
6.34
x
|
7.68
x
|
3.72
x
|
1.16
x
|
EV / EBITDA
|
-3.87
x
|
4.53
x
|
-1.67
x
|
-1.83
x
|
-0.95
x
|
-0.79
x
|
-1.44
x
|
-1.44
x
|
EV / FCF
|
-5.11
x
|
4.3
x
|
-2.02
x
|
-2.16
x
|
-1.01
x
|
-1.27
x
|
-2.66
x
|
-5.87
x
|
FCF Yield
|
-19.6%
|
23.3%
|
-49.6%
|
-46.3%
|
-98.8%
|
-78.5%
|
-37.5%
|
-17%
|
Price to Book
|
3.96
x
|
2.43
x
|
1.45
x
|
1.81
x
|
1.63
x
|
1.59
x
|
1.45
x
|
1.01
x
|
Nbr of stocks (in thousands)
|
51,818
|
52,045
|
58,908
|
59,494
|
60,033
|
60,182
|
-
|
-
|
Reference price
2 |
72.19
|
86.51
|
42.54
|
38.14
|
21.67
|
13.69
|
13.69
|
13.69
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.868
|
1,114
|
6.308
|
7.686
|
86.46
|
42.68
|
132.7
|
303.3
|
EBITDA
1 |
-705.8
|
626.6
|
-456.7
|
-545.9
|
-578.5
|
-417
|
-342.5
|
-243.1
|
EBIT
1 |
-708.1
|
624
|
-460.9
|
-547
|
-579.8
|
-428.6
|
-351.2
|
-213.3
|
Operating Margin
|
-10,310.48%
|
56%
|
-7,306.74%
|
-7,116.69%
|
-670.69%
|
-1,004.18%
|
-264.61%
|
-70.35%
|
Earnings before Tax (EBT)
1 |
-680.2
|
606.1
|
-457.9
|
-532.8
|
-541.5
|
-398.9
|
-328.1
|
-174.5
|
Net income
1 |
-680.2
|
606.1
|
-457.9
|
-532.8
|
-541.5
|
-397.6
|
-330.1
|
-200.9
|
Net margin
|
-9,904.46%
|
54.4%
|
-7,258.91%
|
-6,931.88%
|
-626.32%
|
-931.45%
|
-248.69%
|
-66.26%
|
EPS
2 |
-13.38
|
11.43
|
-7.800
|
-8.980
|
-9.050
|
-6.577
|
-5.196
|
-2.917
|
Free Cash Flow
1 |
-534.5
|
660.8
|
-378.6
|
-461
|
-541.1
|
-257.3
|
-185.3
|
-59.77
|
FCF margin
|
-7,781.84%
|
59.31%
|
-6,001.17%
|
-5,997.57%
|
-625.92%
|
-602.85%
|
-139.6%
|
-19.71%
|
FCF Conversion (EBITDA)
|
-
|
105.46%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
109.03%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.642
|
1.582
|
1.501
|
1.739
|
2.865
|
3.294
|
2.474
|
2.716
|
77.97
|
7.902
|
9.194
|
11.57
|
14.37
|
24.42
|
34.21
|
EBITDA
1 |
-125.2
|
-119.4
|
-125.5
|
-140.1
|
-153.6
|
-158.3
|
-174.5
|
-182.9
|
-35.48
|
-118.9
|
-90.1
|
-78.7
|
-72.3
|
-
|
-
|
EBIT
1 |
-125.5
|
-123.2
|
-128.4
|
-141.5
|
-153.9
|
-155.5
|
-170.5
|
-178.2
|
-42.07
|
-117.7
|
-107.5
|
-103
|
-98.99
|
-93.25
|
-81.39
|
Operating Margin
|
-7,642.33%
|
-7,787.55%
|
-8,554.76%
|
-8,135.71%
|
-5,371.8%
|
-4,719.79%
|
-6,889.94%
|
-6,562.96%
|
-53.96%
|
-1,489.18%
|
-1,169.56%
|
-890.38%
|
-689.01%
|
-381.93%
|
-237.92%
|
Earnings before Tax (EBT)
1 |
-124.7
|
-122.1
|
-126.3
|
-137.3
|
-147.1
|
-146.8
|
-160.3
|
-201.6
|
-32.71
|
-108.5
|
-100.1
|
-96.17
|
-92.14
|
-80.59
|
-76.58
|
Net income
1 |
-124.7
|
-122.1
|
-126.3
|
-137.3
|
-147.1
|
-146.8
|
-160.3
|
-201.6
|
-32.71
|
-108.5
|
-100.3
|
-95.92
|
-91.88
|
-80.59
|
-76.58
|
Net margin
|
-7,595.13%
|
-7,715.23%
|
-8,411.73%
|
-7,896.66%
|
-5,135.99%
|
-4,457.44%
|
-6,480.4%
|
-7,423.78%
|
-41.95%
|
-1,372.85%
|
-1,091.46%
|
-829.34%
|
-639.53%
|
-330.06%
|
-223.87%
|
EPS
2 |
-2.120
|
-2.070
|
-2.130
|
-2.310
|
-2.470
|
-2.460
|
-2.680
|
-3.370
|
-0.5500
|
-1.800
|
-1.672
|
-1.600
|
-1.532
|
-1.573
|
-1.473
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/3/22
|
8/2/22
|
11/8/22
|
2/16/23
|
5/2/23
|
8/7/23
|
11/7/23
|
2/14/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,008
|
1,661
|
1,742
|
1,272
|
753
|
496
|
330
|
473
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-534
|
661
|
-379
|
-461
|
-541
|
-257
|
-185
|
-59.8
|
ROE (net income / shareholders' equity)
|
-75.3%
|
42%
|
-24.1%
|
-35.7%
|
-49.5%
|
-50%
|
-31.8%
|
-10.1%
|
ROA (Net income/ Total Assets)
|
-66.8%
|
39.1%
|
-23%
|
-33.5%
|
-45.4%
|
-59.9%
|
-26.9%
|
-6.76%
|
Assets
1 |
1,018
|
1,551
|
1,992
|
1,591
|
1,193
|
663.3
|
1,228
|
2,973
|
Book Value Per Share
2 |
18.20
|
35.50
|
29.30
|
21.00
|
13.30
|
8.590
|
9.410
|
13.50
|
Cash Flow per Share
2 |
-10.40
|
12.50
|
-6.450
|
-7.760
|
-9.030
|
-4.930
|
-3.560
|
-0.6300
|
Capex
1 |
5.75
|
0.35
|
0.37
|
0.94
|
0.55
|
2.62
|
3.01
|
3.11
|
Capex / Sales
|
83.74%
|
0.03%
|
5.9%
|
12.19%
|
0.64%
|
6.15%
|
2.27%
|
1.03%
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
13.69
USD Average target price
22.22
USD Spread / Average Target +62.32% Consensus |
1st Jan change
|
Capi.
|
---|
| -34.31% | 824M | | -2.73% | 103B | | +1.61% | 95.28B | | +1.95% | 22.15B | | -15.47% | 21.02B | | -8.42% | 18.15B | | -41.01% | 16.73B | | -13.49% | 16.05B | | +3.73% | 13.68B | | +35.01% | 12.17B |
Bio Therapeutic Drugs
|